LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Jazz Pharmaceuticals PLC

Closed

SectorHealthcare

106.85 -0.19

Overview

Share price change

24h

Current

Min

106.35

Max

108.93

Key metrics

By Trading Economics

Income

-284M

-93M

Sales

-190M

898M

P/E

Sector Avg

14.505

50.291

EPS

1.68

Profit margin

-10.307

Employees

2,800

EBITDA

-275M

109M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+69.97% upside

Dividends

By Dow Jones

Next Earnings

30 lip 2025

Market Stats

By TradingEconomics

Market Cap

-939M

6.5B

Previous open

107.04

Previous close

106.85

News Sentiment

By Acuity

26%

74%

56 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Jazz Pharmaceuticals PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 lis 2024, 14:45 UTC

Major Market Movers

Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

31 paź 2024, 15:29 UTC

Major Market Movers

Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation

Peer Comparison

Price change

Jazz Pharmaceuticals PLC Forecast

Price Target

By TipRanks

69.97% upside

12 Months Forecast

Average 182.73 USD  69.97%

High 230 USD

Low 147 USD

Based on 14 Wall Street analysts offering 12 month price targets forJazz Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 111.22Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

56 / 380 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$